OncoCore

Molecular

IMMUNOTHERAPY BIOMARKERS: MSI, MMR, PD-L1

Genes associated with targeted therapy, prognosis, and drug resistance
AKT1, ALK, ARAF, BCL2L11, BRAF, CYP2C19, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, GNA11, GNAQ, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1, MET, MTOR, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, RET

Fusion Variants
ALK, BRAF, ESR1, FGFR1, FGFR2, FGFR3, MET, NRG1, NTRK1, NTRK2, NTRK3, PDGFB, PDGFRA, RET, ROS1

Average TAT: 3-4 days

Specimen Requirements: FFPE block or 10-15 unstained slides

Methodology: NGS

Disease Group: Solid tumor

Somatic